Andreas Krebs
CIK: 0001438946
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)1 (33.3%)
Derivative conversions
Awards (A)2 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
DFTX
Definium Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Sep 18, 2026DFTX
Definium Therapeutics, Inc.
Exercise(M)Direct1.6K shares at avg. $35.52$58K - Jun 11, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct4.7K shares- - Jun 12, 2025MNMD
Mind Medicine (MindMed) Inc.
Award(A)DirectStock Option (Right to Buy)
75.2K shares-
1-3 of 3 transactions
About Krebs Andreas
Krebs Andreas (SEC CIK 0001438946) files insider reports with the SEC as Director of Definium Therapeutics, Inc. (DFTX).
Signal8 holds 3 ownership filings by Krebs Andreas, all Form 4s, filed between Jun 16, 2025 and Sep 18, 2026. Those filings report 3 transactions, from Jun 12, 2025 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Krebs Andreas's filings is in NEW YORK, NY.
Recent filings by Krebs Andreas
Other insiders filing for Definium Therapeutics, Inc. (DFTX)
- Karlin Daniel, Chief Medical Officer
- Barrow Robert, Chief Executive Officer
- Wiley Matthew T., Chief Commercial Officer
- Sullivan Mark, Chief Legal Officer
- Roberts Brandi, Chief Financial Officer
- Vallone Carol A, Director